Risk of Serious Blood Clots Up To 6 Months After COVID-19

Risk of Serious Blood Clots Up To 6 Months After COVID-19

A study from Sweden finds an increased risk of deep vein thrombosis (a blood clot in the leg) up to three months after COVID-19 infection, pulmonary embolism (a blood clot in the lung) up to six months, and a bleeding event... read more

Post COVID-19 Pulmonary Fibrosis

Post COVID-19 Pulmonary Fibrosis

Pulmonary fibrosis is a frequently reported COVID-19 sequela in which the exact prevalence and risk factors are yet to be established. This meta-analysis aims to investigate the prevalence of post-COVID-19 pulmonary fibrosis... read more

Myopericarditis Following COVID-19 Vaccination and Non-COVID-19 Vaccination

Myopericarditis Following COVID-19 Vaccination and Non-COVID-19 Vaccination

The overall incidence of myopericarditis from 22 studies (405,272,721 vaccine doses) was 33·3 cases (95% CI 15·3–72·6) per million vaccine doses, and did not differ significantly between people who received COVID-19... read more

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19

Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support–free days within 21 days. The... read more

External Chest-wall Compression in Prolonged COVID-19 ARDS with Low-compliance

External Chest-wall Compression in Prolonged COVID-19 ARDS with Low-compliance

SARS-CoV-2 can lead to severe respiratory failure (C-ARDS) with some clinical and radiological characteristics that match the presentation of acute respiratory distress syndrome (ARDS). The management of mechanical ventilation... read more

Prevalence of COVID-19-Associated Pulmonary Aspergillosis

Prevalence of COVID-19-Associated Pulmonary Aspergillosis

First reports of cases and case series of COVID-19-associated pulmonary aspergillosis (CAPA) emerged during the first months of the pandemic. Prevalence rates varied widely due to the fact that CAPA was, and still remains,... read more

How Autoimmune Disease Risks Increases After COVID-19

How Autoimmune Disease Risks Increases After COVID-19

The link between COVID-19 infection and development of autoimmune disease is becoming more pronounced, and fields including dermatology are seeking answers to what drives it all. A late-breaking session at the American... read more

tPA for Critically Ill ICU Patients with COVID-19: Does Alteplase Help?

tPA for Critically Ill ICU Patients with COVID-19: Does Alteplase Help?

How do you define a last-ditch effort to save someone's life from COVID-19? Perhaps giving tPA to a severe COVID patient? At this point, I am certain many of us have attempted, with informed consent of course, therapies for... read more

Thromboinflammation and Antithrombotics in COVID-19

Thromboinflammation and Antithrombotics in COVID-19

Thrombotic complications of SARS-CoV-2 infection were recognized early in the pandemic, when infected patients often presented with abnormal coagulation findings and acute macrovascular obstruction, and evidence of pulmonary... read more

Music Therapy Intervention to Treat Sedation-Related Delirium in Critical Care

Music Therapy Intervention to Treat Sedation-Related Delirium in Critical Care

Sedation is an essential component of treatment for some patients admitted to the intensive care unit, but it carries a risk of sedation-related delirium. Sedation-related delirium is associated with higher mortality and... read more

Risks and Burdens of Incident Diabetes in Long COVID

Risks and Burdens of Incident Diabetes in Long COVID

In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during... read more

Comparative analysis of the risks of hospitalisation and death associated with COVID-19 variants in England

Comparative analysis of the risks of hospitalisation and death associated with COVID-19 variants in England

The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age. Underlying the observed risks... read more

Association Between Dexamethasone Treatment for COVID-19 Patients and Rates of Hospital Readmission and Mortality

Association Between Dexamethasone Treatment for COVID-19 Patients and Rates of Hospital Readmission and Mortality

Current guidelines recommend use of dexamethasone, 6 mg/d, up to 10 days or until discharge for patients hospitalized with COVID-19. Whether patients who received less than 10 days of corticosteroids during hospitalization... read more

Electronic Pneumonia Decision Support Helps Reduce Mortality by 38% in Community Hospitals

Electronic Pneumonia Decision Support Helps Reduce Mortality by 38% in Community Hospitals

Pneumonia was the leading cause of death from infectious diseases in the United States, even before the COVID-19 pandemic, and continues to be a leading cause of death. In the study, researchers at Intermountain Healthcare... read more